Running Head: fMRI assessment of motor learning and escitalopram

### Modulation of premotor cortex response to sequence motor learning during escitalopramintake

Eóin N. Molloy<sup>1,2,3,4</sup>, Karsten Mueller<sup>2,5</sup>, Nathalie Beinho  $\Box lzl^{1,3}$ , Maria Blöchl<sup>2,3,8</sup>, Fabian A. Piecha<sup>1,3</sup>, André Pampel<sup>5</sup>, Christopher J. Steele<sup>3,12</sup>, Ulrike Scharrer<sup>1,3</sup>, Gergana Zheleva<sup>1,3</sup>, Ralf Regenthal<sup>9</sup>, Bernhard Sehm<sup>3,7,13</sup>, Vadim V. Nikulin<sup>3,6</sup>, Harald E. Mo  $\Box ller^{2,5}$ , Arno Villringer<sup>2,3,4,10,11</sup> & Julia Sacher<sup>1,2,3,10</sup>

Emotion & Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences<sup>1</sup> International Max Planck Research School NeuroCom<sup>2</sup>

Dept. of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences<sup>3</sup>

Faculty of Medicine, Leipzig University<sup>4</sup>

Nuclear Magnetic Resonance Unit, Max Planck Institute for Human Cognitive and Brain Sciences<sup>5</sup>

Centre for Cognition and Decision Making, Institute for Cognitive Neuroscience, National Research University Higher School of Economics<sup>6</sup>

Neuroplasticity & Motor Recovery Group, Max Planck Institute for Human Cognitive and Brain Sciences<sup>7</sup> Dept. of Psychology, University of Münster<sup>8</sup>

Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, Leipzig University<sup>9</sup>

Clinic for Cognitive Neurology<sup>10</sup>

Berlin School of Mind and Brain<sup>11</sup>

Dept. of Psychology, Concordia University<sup>12</sup>

Dept. of Neurology, Martin Luther University Halle-Wittenberg<sup>13</sup>

Correspondence:

Eoin N. Molloy, MSc - Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany, molloy@cbs.mpg.de, tel: +49 341 9940-2215

Julia Sacher, MD, PhD - Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany, sacher@cbs.mpg.de, tel: +49 341 9940-2409

Running Title: fMRI assessment of motor learning and escitalopram

Figures: 4, Tables: 3 Supplementary Figures: 1, Supplementary Tables: 4

Word Count (including headings):

Abstract: 149 Introduction: 643 Materials and Methods: 1492 Results: 590 Discussion: 1382 Total (Including

Abstract):

4256

#### Running Head: fMRI assessment of motor learning and escitalopram

#### Abstract:

The contribution of selective serotonin reuptake inhibitors (SSRIs) to motor learning by inducing motor cortical plasticity remains controversial given diverse findings from positive preclinical data to negative findings in recent clinical trials. To empirically address this translational disparity, we use functional magnetic resonance imaging (fMRI) in a double-blind, randomized controlled study to assess whether 20 mg escitalopram improves sequence-specific motor performance and modulates cortical motor response in 64 healthy female participants. We found decreased left premotor cortex responses during sequence-specific learning performance comparing single dose and steady escitalopram state. Escitalopram plasma-levels negatively correlated with the premotor cortex response. We did not find evidence in support of improved motor performance after a week of escitalopram-intake. These findings do not support the conclusion that 1-week escitalopram intake increases motor performance but could reflect early adaptive plasticity with improved neural processing underlying similar task performance when steady peripheral escitalopram levels are reached.

 Key words: selective serotonin reuptake inhibitors, sequential motor learning, neural plasticity,

 functional

#### Running Head: fMRI assessment of motor learning and escitalopram

### 1 Introduction:

Motor learning is the improved performance of a motor task following practice<sup>1</sup> and is modulated 2 by monoaminergic transmission in cortical and subcortical motor networks<sup>2,3,4</sup>. Research on this 3 monoaminergic basis of motor learning typically focuses on dopamine signaling in both health<sup>5,6</sup> 4 and disease<sup>7</sup>. Evidence from rodents<sup>8</sup> and stroke patients<sup>9</sup>, however, suggests that serotonin also 5 6 critically modulates motor behavior. Selective serotonin reuptake inhibitors (SSRIs), commonly prescribed medications for depression and anxiety disorders<sup>10</sup>, increase extracellular serotonin 7 and successfully treat post-stroke depression<sup>11</sup>. In the absence of depressive symptoms, several 8 9 studies have also demonstrated an effect of SSRIs on the recovery of post-stroke motor dvsfunction<sup>12</sup>. Notably, the FLAME trial (Fluoxetine for Motor Recovery After Acute Ischemic 10 11 Stroke<sup>9</sup>) showed approximately 50% motor recovery in 57 patients following combined 12 fluoxetine treatment and physiotherapy, in a multi-center Randomized Controlled Trial (RCT). 13 These findings were further supported by a meta-analysis of 52 RCTs in 4,060 patients, which, 14 however, also acknowledged heterogeneity and methodological shortcomings in a substantial 15 proportion of trials<sup>13</sup>.

16

17 Possible mechanisms underlying SSRI modulation of motor performance and learning include anti-inflammatory<sup>14,15</sup> and neurotrophic effects<sup>16</sup> such as increased neurogenesis<sup>17</sup>, proliferation<sup>18</sup>, 18 protein expression enhancement<sup>19</sup>, upregulation of beta1-adrenergic receptors<sup>20</sup>, downregulation 19 of GABA-transmission<sup>21,22</sup>, and hippocampal long-term potentiation<sup>23</sup>. These findings suggest 20 21 that SSRIs may increase responsivity to environmental stimuli, possibly via changes in inhibitory and excitatory balance<sup>24</sup> and reorganization of cortical networks<sup>25-27</sup>. Studies in humans have 22 23 provided support for this by demonstrating changes in resting state functional connectivity induced by a single dose of escitalopram<sup>28</sup>. Additionally, decreases in resting state alpha-24 frequency band induced by tryptophan depletion<sup>29</sup>, which are hypothesized to reflect alterations 25

#### Running Head: fMRI assessment of motor learning and escitalopram

in the excitatory and inhibitory balance of cortical networks, have been observed in healthy
volunteers. Moreover, preliminary functional magnetic resonance imaging (fMRI) evidence has
linked decreased functional responses in the motor network with improved motor performance
following fluoxetine administration<sup>30-33</sup>.

30

Recent large-scale RCTs in stroke patients such as the TALOS<sup>34</sup> and FOCUS trials<sup>35</sup>, involving 31 32 over 642 and 3,000 patients, respectively, however, do not suggest beneficial effects of SSRIs on 33 functional recovery. Critically, however<sup>36</sup>, these RCTs were conducted against the backdrop of 34 routinely available rehabilitation and did not combine SSRI administration with a clearly defined 35 motor learning paradigm, nor did they assess functional brain responses to SSRI intake. As a 36 result, no previous study, either in healthy participants or in patients, has successfully leveraged 37 prolonged training on an established motor learning paradigm in combination with SSRI-38 administration and fMRI in an adequately powered sample. Therefore, the hypothesis of whether 39 SSRI administration, specifically in combination with an established motor learning paradigm, 40 induces a beneficial effect on motor learning performance and changes the cortical motor 41 response underlying the learning performance, remains to be tested empirically.

42

43 The current study utilizes fMRI to address whether one week of SSRI administration in 44 combination with a sequential motor learning task improves sequence specific motor 45 performance and elicits changes in concurrent cortical motor response during task performance. 46 In a double-blind, randomized controlled pharmaco-fMRI study, we administered 20 mg (to reach 80% serotonin transporter (5-HTT) occupancy)<sup>37</sup> of escitalopram, the most 5-HTT selective 47 and rapid onset SSRI<sup>38,39</sup> or placebo, to healthy females undergoing parallel fMRI assessment and 48 training on a variant of the sequential pinch force task (SPFT)<sup>40</sup>. We chose a healthy 49 homogeneous and young sub-sample to avoid variance associated with pathology<sup>41,42</sup>, sex<sup>33</sup>, and 50

# Running Head: fMRI assessment of motor learning and escitalopram

51	age <sup>43</sup> . Our <i>a priori</i> hypotheses were (1) that one week of escitalopram intake would improve					
52	sequential motor performance relative to placebo, as assessed by performance in a temporal lag					
53	condition on the SPFT, calculated as the time difference between a computer controlled visual					
54	stimulus and participant control of a pinch-force device. (2) By specifying this sequence-learning					
55	condition in an fMRI contrast (hereafter referred to as the learning contrast, i.e., the difference of					
56	functional brain responses between two experimental conditions comprising two levels of task					
57	difficulty), we also hypothesized escitalopram-induced changes in fMRI-response in core					
58	components of the motor network during task performance.					

#### Running Head: fMRI assessment of motor learning and escitalopram

#### 59 Materials and methods:

#### 60 **Participants & eligibility:**

61 Eligible individuals were right-handed, aged 18-35 years, with a body mass index (BMI) 18.5-25  $kg/m^2$ , without history of neurological or psychiatric illness, and female on oral contraceptives 62 for  $\leq 3$  months<sup>44,45</sup> to eliminate sex and hormone-dependent escitalopram responsivity<sup>46</sup>. 63 64 Exclusion criteria were medication use, contraindications for MRI, tobacco use, alcohol abuse, 65 positive drug or pregnancy tests, professional musicianship and athleticism, and abnormal QT 66 times in electrocardiogram screenings. In total, 88 participants were screened with 71 enrolled. 67 Analyses included 64 volunteers for the behavioral analysis as 6 (escitalopram=4) chose to 68 discontinue participation and n=1 (placebo) was excluded due to a pre-analytical error in plasma 69 sample acquisition. Sixty volunteers were included in functional imaging analysis as 4 were 70 excluded due to MRI data quality concerns (2 escitalopram) due to head movement. 1 volunteer 71 from the placebo group was excluded due to an artefact in an anatomical sequence and 1 72 participant from the escitalopram group was excluded due to an artefact detected during 73 acquisition of the functional sequence (Supplementary Figure 1).

74

### 75 Study design and procedure:

76 The Ethics committee of the Faculty of Medicine, Leipzig University approved all procedures 77 (approval number 390/16-ek) and the study was pre-registered at clinicaltrials.gov (ID: 78 NCT03162185). Participants were randomized to receive either 20 mg of escitalopram or placebo 79 (mannitol/aerosol) orally for 7 days. Randomization was performed by the Central Pharmacy of 80 Leipzig University with equal condition allocation. Sequential motor training was conducted 5 81 times (baseline, on day 1 of escitalopram administration, days 5 and 6 of drug administration, and 82 at steady state – after 7 days) (Figure 1). Functional magnetic resonance imaging data (fMRI) and 83 serum mature brain-derived neurotrophic factor (mBDNF) samples were acquired at baseline,

#### Running Head: fMRI assessment of motor learning and escitalopram

84 single dose, and steady state. Electrocardiogram recordings were conducted at single dose, day 4, 85 and steady state to monitor potential changes in QT intervals. Adverse reactions to escitalopram were recorded using the antidepressant side-effects checklist (ASEC)<sup>47</sup>. All participants remained 86 87 under medical supervision during the experiment. Concentrations of escitalopram in plasma was 88 assessed chromatographically using a quality control sample. Deviation of the measured 89 escitalopram concentration of the sample was tested for an acceptance interval of  $\pm 15\%$ . All 90 behavioral and fMRI assessments took place 3 hours after escitalopram or placebo intake to allow 91 for escitalopram to reach maximum levels in serum<sup>48</sup>.

92 \*Figure 1\*

# 93 Sequential pinch force task:

94 We assessed sequence motor learning using a variant of the sequential pinch force task (SPFT), 95 with Presentation (v16.5) running on WindowsXP. Baseline, single dose, and steady state 96 measurements took place during fMRI, while day 5 and day 6 were conducted outside the 97 scanner on an identical separate device. Task completion involved controlling the rise and fall of 98 a yellow bar (force) via the participant's thumb and index finger (attenuated to individual 99 strength) while attempting to match the speed of a moving computer controlled blue reference bar 100 (Figure 1). We measured performance in two conditions: (1) a control condition, where the 101 reference bar moves sinusoidally and (2) a sequence-specific learning condition, in which the 102 reference moves in a sequential pattern that remains stable across sessions. A rest condition 103 punctuated training to avoid fatigue. Each session consisted of 5 blocks with 3 trials per block 104 and cycled through simple, rest, and learning. Participants received no feedback regarding 105 performance. To assess performance, we calculated the time difference (lag) in milliseconds 106 between the reference and force bar during the learning trials.

#### Running Head: fMRI assessment of motor learning and escitalopram

### 107 **Demographic data and statistical analysis:**

- 108 Independent samples *t*-tests using the R statistical programming language<sup>49</sup> tested for potential
- 109 group differences in age, BMI, downregulated hormonal profile, and on total ASEC scores at
- 110 single dose and steady state. A power analysis conducted using G\*Power<sup>50</sup> (v.3.1.9.4) assuming
- 111 statistical power of 95% to detect a significant effect of escitalopram on sequence motor learning
- 112 (i.e. learning rate over 5 behavioral assessments compared to placebo) with a small effect size
- and an  $\alpha$ -level of <0.05 suggested a minimum sample size of 56, with 28 participants per group.
- 114 To account for potential drop-outs, we aimed to include 60 participants in total.

# 115 Behavioral data preprocessing:

All SPFT data were preprocessed using in house Matlab scripts. Quality control used an outlier labeling approach<sup>51</sup> implemented in Python (v2.7.15) in which trial, condition, group, and outcome specific interquartile ranges were multiplied by a factor of 1.5 to compute upper and lower bound thresholds.

#### 120 Behavioral data analysis:

- 121 All behavioral data analyses were conducted using R.
- (1) Independent samples *t*-tests assessed baseline group differences using the 't.test' function toassess efficacy of randomization.
- 124 (2) Comparisons between groups over time employed an omnibus linear random-intercept mixed
- 125 effect modeling approach using the 'lmer' function, within the 'lme4' package in R (independent
- 126 factors: group, time, dependent variable: lag). Contributions of each fixed effects were assessed
- 127 with a likelihood ratio test for improvement of model fit.

#### Running Head: fMRI assessment of motor learning and escitalopram

128	(3) Post-hoc independent samples <i>t</i> -tests were conducted on mean single dose and steady state				
129	scores to assess potential group differences at each critical time point of escitalopram-				
130	administration. Additionally, the delta (difference between mean performance at steady state				
131	compared to baseline) was compared between groups for each outcome via independent samples				
132	t-tests. Bayes Factor t-tests using the 'ttestBF' function in the 'BayesFactor' package assessed the				
133	likelihood of the null hypothesis for all independent sample analyses.				

- 134 (4) Pearson's correlation analyses assessed potential associations between total ASEC scores and
- 135 mean lag performance at both single dose and steady state.
- 136 **fMRI data acquisition:**

137 fMRI data were acquired with gradient-echo echo planar imaging (EPI) on a 3-Tesla

138 MAGNETOM Verio scanner (Siemens, Erlangen, Germany, 32-channel head-coil, flip angle 90°,

139 TR=2000 ms, TE=30 ms, field of view=192×192 mm<sup>2</sup>, 30 slices,  $64\times64$  matrix,  $3\times3\times3$ mm<sup>3</sup>

140 nominal resolution, 495 volumes, aligned -15° along the anterior to posterior commissure, ~16

141 minutes). A whole-brain three dimensional T1-weighted Magnetization Prepared Rapid Gradient-

142 echo (MPRAGE) was also acquired at each time point for co-registration<sup>52</sup> with inversion time,

143 TI=900 ms, TR=2300 ms, TE=2.98 ms,  $1 \times 1 \times 1$  mm<sup>3</sup> nominal isotropic resolution, ~9 minutes<sup>53</sup>.

### 144 fMRI data analysis – Preprocessing and first-level analysis:

Data pre-processing was conducted using SPM12 (v12.7219). Data were realigned, unwarped, normalized to Montréal Neurological Institute (MNI) space, and smoothed with a Gaussian kernel (8mm at full-width-half-maximum). First level analysis was performed for baseline, single dose and steady state separately using a general linear model (GLM) including all three experimental conditions: learning, simple, and rest. In addition, each analysis contained headmovement parameters obtained during preprocessing motion correction. Following parameter

#### Running Head: fMRI assessment of motor learning and escitalopram

- 151 estimation, we generated contrast images specific to sequence learning by specifying the learning
- 152 contrast (i.e., the difference between the learning and simple conditions).

### 153 fMRI data analysis – Group-level analysis:

Using contrast images obtained at the first level, second level analyses were performed with SPM12 in Matlab (v9.7). Results were considered statistically significant at a cluster-defining threshold of p<0.001 corrected at p<0.05 using family-wise error (FWE) for multiple comparisons at the cluster-level.

(1) An independent-samples *t*-test assessed potential differences in the learning contrast betweengroups at baseline.

160 (2) Following baseline comparisons, we assessed changes across time within the escitalopram 161 group. Using a paired *t*-test, we each compared baseline to single dose, baseline to steady state, 162 and single dose to steady state. Both directions of each *t*-statistic were assessed to test for both 163 increases and decreases in fMRI response during the learning contrast over time.

164 (3) To investigate group differences with respect to results obtained in analyses (2), we specified 165 a flexible factorial model using factors for *subject* (for repeated measurements), *time* and *group*. 166 Comparisons from (2) yielding a significant difference were repeated within this model to 167 validate results from paired *t*-tests. Within this model, we tested for an interaction between group 168 and *time*. Additionally, a sensitivity analysis repeated this interaction analysis with an additional 169 regressor. Two mean behavioral measures for each participant (one for each timepoint) were entered as nuisance covariates in the GLM<sup>54</sup>. For these behavioral measures, we used the 170 171 behavioral sequence-specific learning measure "lag learning-simple score" (LLSS), as calculated 172 for each participant by subtracting the mean simple condition scores from the mean learning 173 condition lag scores.

#### Running Head: fMRI assessment of motor learning and escitalopram

(4) To visualize mean signal for the learning contrast for each group at baseline, single dose, and
steady state, a series of one-sample *t*-tests was conducted on each group at each timepoint
separately.

177 (5) In order to test for a correlation between motor performance improvement and change in the 178 learning contrast within the escitalopram group, we used the LLSS as an effect of interest within 179 a second flexible factorial design<sup>54</sup>. Here, the model was generated using the factors *subject*,

180 group, and LLSS.

181 (6) With the aim of testing for a correlation between escitalopram plasma and brain kinetics

182 during the learning contrast, escitalopram plasma levels were entered as an effect of interest

183 within a third flexible factorial design<sup>54</sup>, within the escitalopram group, using the factors *subject*,

184 group, and plasma escitalopram levels.

### 185 Analysis of serum mature BDNF levels:

A one-way repeated measures ANOVA was implemented in R using the 'Anova' function to assess changes in serum mBDNF levels across time. Paired samples *t*-tests in both the escitalopram and placebo groups compared baseline to steady state within each group, separately.

#### Running Head: fMRI assessment of motor learning and escitalopram

#### 189 **Results:**

### 190 **Demographics:**

- 191 No differences were observed between groups in any baseline screening measures. Escitalopram
- 192 levels were within the expected range<sup>49</sup> (Table 1).
- 193 **\*Table 1\***

### 194 Sequence-specific motor learning:

- 195 We did not find any significant differences between the escitalopram and placebo groups on
- 196 behavioral measures of sequence-specific motor learning:
- 197 (1) Group comparisons of mean performance at baseline did not show any significant group
- 198 differences in sequence-specific motor learning behavior (t=-0.25, p=0.80).
- 199 (2) For group comparisons over time, a mixed effects model including a fixed effect of *time* fit
- 200 the data significantly better than a random-intercept only model, reflecting a decrease in lag
- 201 scores (Table 2). The fixed effect of *group* and the interaction of *time* and *group* did not show a
- 202 significant improvement in fit, demonstrating that, while both groups improved in sequence-
- 203 specific motor performance over time, they did so comparably (Figure 2).

204 (3) Post-hoc two-sample *t*-tests did not show a significant group difference in mean performance

at either single dose or steady state. Comparisons of the delta scores from baseline to steady state

206 did not show any significant differences between groups. Bayes Factor analysis of group

207 comparisons at single dose and steady, as well as the delta, yields moderate evidence in support208 of the null hypothesis (Table 2).

- 209 (4) Additionally, correlation analyses did not show an association between total ASEC scores
- 210 with mean behavioral lag scores at either single dose (r=-0.03, p=0.8,) or at steady state (r=0.11
- 211 *p*=0.37), respectively.

212 \*Figure 2\*

- 213
- 214 **\*Table 2\***

215

#### Running Head: fMRI assessment of motor learning and escitalopram

### 216 Functional MRI responses during sequence-specific motor learning:

(1) We did not observe any group differences in the learning contrast fMRI responses at baseline.

(2) Within the escitalopram group, we found a significant decrease of the learning contrast in
bilateral motor regions (Figure 3, escitalopram panel, blue overlay) when comparing single dose
with steady state. We did not observe any significant increases in whole-brain fMRI signal for
this learning contrast.

(3) Comparisons of groups over time reveals decreases in the learning contrast in the left premotor cortex of the escitalopram group between single dose and steady state that are not observed in placebo (Figure 3, interaction panel, yellow overlay). A sensitivity analysis controlling for intra-subject variance in task performance replicates this result, showing a significant *group* by *time* interaction with a decrease in the learning contrast from single dose to steady state in the escitalopram group in the left premotor cortex (Table 3).

228 (4) One-sample *t*-tests across the learning contrast images in each group at each time point show

- bilateral activation in both the escitalopram and placebo groups at each of baseline, single dose,
- and steady state (Figure 3).

231 **\*Figure 3\*** 

232

233 **\*Table 3\*** 

(5) Correlation analysis between the change in sequence-specific learning performance with the fMRI signal change in the learning contrast from single dose to steady state within the escitalopram group reveals a significant positive correlation in brain regions including the left premotor cortex (Figure 4; yellow overlay, Supplementary Table 3).

(6) Correlational analysis between escitalopram plasma levels and the learning contrast in the
escitalopram group shows a significant negative correlation, with increases in escitalopram
plasma concentration associated with decreases in the learning contrast in the left supplementary
motor area and supramarginal gyrus (Figure 4, Supplementary Table 4).

242 **\*Figure 4\*** 

Running Head: fMRI assessment of motor learning and escitalopram

### 243 Analysis of mature BDNF levels:

- 244 Analysis of mBDNF levels from baseline to steady state in both groups combined does not reveal
- any significant changes over time (F(1, 62) = 2.195, p=0.12), and paired *t*-tests do not indicate
- significant changes from baseline to steady state in either the escitalopram (t = -1.23, p=0.22) or
- 247 placebo group (t =-1.5, p=0.14), respectively.

#### Running Head: fMRI assessment of motor learning and escitalopram

#### 248 **Discussion:**

249 In this randomized controlled interventional study, we investigated whether administration of 20 250 mg escitalopram improves motor learning performance and alters functional brain response in the 251 motor network during sequence motor learning. Results show a significant learning effect in 252 sequence-specific motor performance though this rate of improvement does not differ between 253 groups. Additionally, we do not observe any significant group differences at any time point, or in 254 rate of improvement. With fMRI, we find significant escitalopram-induced decreases in the left 255 cortical premotor response during sequence-specific learning comparing single dose and steady 256 levels of escitalopram. Moreover, consideration of behavioral performance as a variable of 257 interest during this phase of learning reveals that these changes in the sequence-specific learning 258 contrast positively correlate with improvement in motor performance. Finally, we observe a 259 negative correlation between escitalopram-plasma levels and the fMRI response during the 260 sequence-specific learning contrast in the left premotor cortex during task-performance, 261 suggesting a parallel development between escitalopram plasma kinetics and the attenuation of 262 cortical motor response to sequence-specific motor learning.

263

264 The lack of an effect of SSRI-administration on motor learning performance differs from previous findings in healthy vounteers<sup>31-33</sup>. These studies, however, were neither powered nor 265 266 pre-registered to test this as an *a-priori* hypothesis, with six healthy volunteers for five different behavioral tests and one fMRI experiment<sup>31,32</sup> and nineteen volunteers for six different behavioral 267 268 assessments<sup>33</sup>. Additionally, we administered escitalopram, and chose a task that may be less 269 cognitively demanding due to repetitive isotonic contractions<sup>55</sup>, possibly creating earlier ceiling 270 effects in healthy adults. These previous findings could be specific to paroxetine, require tasks 271 with more spatial and coordination-oriented sensorimotor components, or may only become 272 apparent after several weeks of administration. Nevertheless, given that we administered the

#### Running Head: fMRI assessment of motor learning and escitalopram

273	SSRI with the highest transporter selectivity <sup>56</sup> , employed a task that reliably measures sequence
274	motor learning <sup>40</sup> , and tested a sample well-powered to detect robust effect sizes, it is unlikely that
275	this discrepancy is due to the choice of SSRI or motor paradigm alone. Furthermore, our
276	exploratory analysis of mature BDNF levels in plasma did not reveal any significant changes
277	associated with improved motor learning performance in either group. While this is consistent
278	with findings of improved motor performance in healthy volunteers to be unrelated to peripheral
279	BDNF levels <sup>57</sup> , evidence supportive of an association between motor skill learning and increased
280	BDNF levels have also been reported <sup>58</sup> . While future studies should assess potential SSRI
281	modulation of motor learning with additional paradigms, our results do not support a beneficial
282	effect of SSRI-administration on motor learning performance in health.

283

284 We do report evidence supportive of our second hypothesis however, with significant decreases 285 in functional responses in left premotor cortex during sequence specific motor learning, relative 286 to placebo (Figure 3). While both increases and decreases in functional brain responses underlie motor learning<sup>59</sup>, this pattern is dependent on differential stages of learning and is defined by 287 multiple parallel processes<sup>60-62</sup>. Early fast learning is accompanied by rapid improvements in 288 performance, followed by slow learning that characterizes a more consolidatory phase<sup>63,64</sup>. 289 290 Patterns of functional responses observed during this phase are also influenced by the type of 291 task, with explicit learning of repetitive and unchanging sequences hypothesized to lead to faster 292 automation of performance  $^{61,65,66}$  and a subsequent reduction in cognitive load needed for task 293 completion. Given the predictable repetition of the learning sequence on our task and the timing 294 of our assessments, it is possible that the observed escitalopram-induced decreases in the learning 295 contrast reflect this automation of responses and subsequent consolidation of sequence learning.

#### Running Head: fMRI assessment of motor learning and escitalopram

296 Such a neural consolidation process in response to 1 week of escitalopram-intake is consistent with a recent conceptual model of SSRI influences on post-stroke recovery<sup>67</sup>. The authors 297 298 propose that acute SSRI exposure changes the excitatory and inhibitory balance with increases in 299 excitatory signaling, allowing for the remodeling of cortical pathways<sup>67</sup>. Subsequent SSRI 300 exposure leads to a reset in homeostasis with a heightening of  $\gamma$ -aminobutyric acid (GABA) 301 tone<sup>67</sup>, allowing for remodeled pathways to become engrained as task performance continues. 302 Further support for this interpretation stems from studies identifying an inverse relationship between cortical GABA concentrations and functional brain responses<sup>68,69</sup> and SSRI 303 304 administration has been shown to increase cortical GABA levels in rodents<sup>70</sup> and healthy volunteers<sup>71</sup>. Finally, the observation that the escitalopram-induced decrease in the learning 305 306 contrast is negatively associated with escitalopram kinetics occurs in a timeframe consistent with that typically required for 5-HT<sub>1A</sub> autoreceptor desensitization<sup>72</sup>, which could also modulate 307 effective enhancement of cortical GABAergic tone<sup>73</sup>. In summary, it is possible that this 308 309 escitalopram-induced decrease in premotor response in the learning contrast reflects more 310 effective neural task processing, relative to placebo, in a region central to temporally and visually-oriented motor learning and planning<sup>74-77</sup>. This interpretation is consistent with the 311 312 hypothesis of an SSRI-induced window of experience-dependent plasticity as an attenuator of neural efficiency during performance<sup>25,26</sup>. 313

314

An alternative explanation of this finding is a habituation effect of neural responses during repetitive sequence-specific motor learning that may be emphasized by escitalopram administration. While we report a significant three-way interaction for brain, task, and group (Figure 4), this effect is limited to the comparison between a single dose and steady state and in the escitalopram group only, despite the observation that both groups successfully improve performance over time. It is possible that the neural responses during task performance in the

### Running Head: fMRI assessment of motor learning and escitalopram

placebo group reflects a simpler order effect, whereby neural responses adapt incrementally,
 rather than via an adaptive plasticity mechanism. Integration of more direct measures of cortical
 excitation and inhibition can allow for more fine-grained investigations into acute and subacute
 SSRI-effects.

325

326 Nevertheless, there are some limitations to consider when interpreting these results. We 327 acknowledge that the initial strong learning effect may have masked more subtle modulation of 328 performance with escitalopram at a later training session. Though a known limitation of this task, 329 we chose the SPFT for this well-established and reliable learning effect. While performance 330 reaches a ceiling during the fourth and fifth sessions, as described previously<sup>40</sup>, we still observe a 331 considerable change in performance after the administration of the single dose and subsequent 332 training sessions, thus maintaining the falsifiability of our primary hypothesis. Second, our results 333 may not generalize to males or older adults as our sub-sample consists only of females with 334 standardized downregulation of ovarian hormones. This was a deliberate *a-priori* restriction to eliminate confounds such as sex-differences<sup>33</sup> and fluctuating endogenous hormones<sup>78</sup> on 335 336 environmental learning and escitalopram responsivity. Third, other studies have gradually increased escitalopram doses for pharmaco-fMRI protocols in healthy participants<sup>79</sup> to minimize 337 adverse effects. We chose a fixed dose of 20 mg to reliably block 80 % of 5-HTT<sup>37</sup>, an approach 338 previously well tolerated<sup>28</sup>. While four participants discontinued protocol because of adverse 339 340 effects in the escitalopram group, this was also the case for two placebo participants, and there 341 was no group difference in self-reported side effects at steady state. Finally, fMRI provides an 342 indirect measure of neural activity, which is susceptible to non-neural changes such as vascular 343 uncoupling. Given the functional specificity of the premotor cortex, it is unlikely that these 344 findings are solely driven by changes in global blood flow. We cannot, however, identify 345 underlying molecular mechanisms, which require quantitative measures such as MR-

#### Running Head: fMRI assessment of motor learning and escitalopram

- 346 spectroscopy measures of GABA and glutamate or  $[^{11}C]UCB$ -J positron emission tomography, a
- 347 recently developed technique for *in vivo* imaging of synaptic plasticity<sup>80,81</sup>.
- 348

349 In conclusion, this is the first study to investigate the effect of steady escitalopram administration 350 on motor learning in an established sequential motor learning paradigm and the associated brain 351 response in a sufficiently powered sample. In this pre-registered, randomized, controlled, 352 interventional study, we do not find evidence in support of improved performance in response to 353 1 week of escitalopram-intake during sequence-specific motor training. A major difference we 354 observe between groups is a decrease in premotor cortical responses during sequence-specific 355 learning performance contrasting single dose and steady drug state. Considering previous 356 findings on sequential motor learning and associated neural correlates in the motor network, less 357 premotor response during similar performance may suggest more effective neural processing and greater consolidation of performance<sup>64</sup>. By combining escitalopram administration and sequence-358 359 specific motor training for one week, we provide the first empirically tested framework for 360 assessing SSRI-effects on human adaptive motor plasticity in health. Our paradigm and findings 361 may help disentangle the seemingly contradictory results between preclinical models and recent 362 clinical trials and represent an important milestone towards understanding the role of SSRIs in 363 human motor learning.

**Running Head:** fMRI assessment of motor learning and escitalopram

## Acknowledgements:

We thank Heike Schmidt-Duderstedt and Kerstin Flake for assisting with preparation of the figures and Dr. Kristin Ihle for her assistance with medical supervision of all participants during

the experiments, and PD Dr. Veronica Witte for statistical discussion.

Running Head: fMRI assessment of motor learning and escitalopram

### **Authors' Contributions Statement:**

ENM: Conceptualization, Investigation, Methodology, Formal analysis, Writing - original draft,

Writing - review & editing, Visualization, Funding acquisition

KM: Conceptualization, Methodology, Formal analysis, Writing - review & editing,

Visualization

- NB: Conceptualization, Methodology
- MB: Formal analysis, Writing review & editing
- FAP: Formal analysis, Writing review & editing

**AP:** Methodology

- CJ: Methodology, Formal analysis
- US: Conceptualization, Methodology
- GZ: Conceptualization, Methodology
- **RR:** Formal analysis, Writing review & editing

**BS:** Writing - review & editing

VVN: Writing - review & editing

HEM: Methodology, Writing - review & editing

AV: Writing - review & editing

JS:: Conceptualization, Investigation, Methodology, Writing - review & editing, Visualization,

Funding acquisition

Running Head: fMRI assessment of motor learning and escitalopram

# **Competing Interests:**

The authors declare that no competing interests exist.

# **Funding:**

This research was supported by the FAZIT Foundation to ENM and The Branco Weiss

Fellowship – Society in Science to JS and the Max Planck Society.

Running Head: fMRI assessment of motor learning and escitalopram

### **References:**

- 1. Diedrichsen, J., Kornysheva, K. (2015). Motor skill learning between selection and execution. *Trends Cogn Sci.* 19(4):227-33. doi: 10.1016/j.tics.2015.02.003.
- Molina-Luna K., Pekanovic, A., Röhrich, S., Hertler, B., Schubring-Giese, M., Rioult-Pedotti, MS., Luft, A.R. (2009). Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. *PLoS One*. 17;4(9):e7082. doi:10.1371/journal.pone.0007082.
- Rioult-Pedotti, MS., Pekanovic, A., Atiemo, CO., Marshall, J., Luft, AR. (2015). Dopamine Promotes Motor Cortex Plasticity and Motor Skill Learning via PLC Activation. *PLoS One*. 10(5):e0124986. doi: 10.1371/journal.pone.0124986.
- 4. Vitrac, C., Benoit-Marand, M. (2017) Monoaminergic Modulation of Motor Cortex Function. *Front. Neural Circuits* 11:72. doi: 10.3389/fncir.2017.00072.
- Flöel, A., Breitenstein, C., Hummel, F., Celnik, P., Gingert, C., Sawaki, L., Knecht, S., Cohen, LG. (2005). Dopaminergic influences on formation of a motor memory. *Ann Neurol.* 58(1):121-30. doi:10.1002/ana.20536.
- Flöel, A., Garraux, G., Xu, B., Breitenstein, C., Knecht, S., Herscovitch, P., Cohen, LG. (2008). Levodopa increases memory encoding and dopamine release in the striatum in the elderly. *Neurobiol Aging*. 29(2):267-79. doi:10.1016/j.neurobiolaging.2006.10.009
- Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinsons Dis.* doi:10.1155/2016/9832839
- Maya Vetencourt, JF., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., O'Leary, OF., Castrén, E., Maffei, L. (2008). The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science*, 320(5874), 385-388. doi:10.1126/science.1150516.
- Chollet, F., Tardy, J., Albucher, JF., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., Guillon, B., Moulin, T., Marque, P., Pariente J, Arnaud, C. Loubinoux, I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol*, 10(2), 123-130. doi:10.1016/S1474-4422(10)70314-8.
- Cipriani, A., Furukawa, TA., Salanti, G., Chaimani, A., Atkinson, LZ., Ogawa, Y., Leucht, S., Ruhe, HG., Turner, EH., Higgins, JPT., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, JPA., Geddes, JR. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network metaanalysis. *Lancet*. 7;391(10128):1357-1366. doi: 10.1016/S0140- 6736(17)32802-7.
- Hackett, ML., Anderson, CS., House, A., Halteh, C. (2006). Interventions for preventing depression after stroke. *Cochrane Database Syst Rev.* 16;(3):CD003689. doi: 10.1002/14651858.CD003689.pub3.

Running Head: fMRI assessment of motor learning and escitalopram

- Acler, M., Robol, E., Fiaschi, A., Manganotti, P. (2009). A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. *Journal of Neurology* 256(7):1152-8. doi: 10.1007/s00415-009-5093-7.
- 13. Mead, GE., Hsieh, CF., Hackett, M. (2013). Selective serotonin reuptake inhibitors for stroke recovery. *JAMA*. 310(10):1066-7. doi: 10.1001/jama.2013.107828.
- Lim, CM., Kim, SW., Park, JY., Kim, C., Yoon, SH., Lee, JK. (2009). Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. *J Neurosci Res.* 87(4):1037-45. doi: 10.1002/jnr.21899.
- 15. Tynan, RJ., Weidenhofer, J., Hinwood, M., Cairns, MJ., Day, TA., Walker, FR. (2012). A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. *Brain Behav Immun.* 26(3):469-79. doi: 10.1016/j.bbi.2011.12.011.
- 16. Schmidt, HD., Duman, RS. (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. *Behav Pharmacol.* 18(5-6):391-418. doi: 10.1097/FBP.0b013e3282ee2aa8
- Malberg, JE., Eisch, AJ., Nestler, EJ., Duman, RS. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci*. 15;20(24):9104-10. doi: https://doi.org/10.1523/JNEUROSCI.20-24-09104.2000.
- Lyons, L., ElBeltagy, M., Umka, J., Markwick, R., Startin, C., Bennett, G., Wigmore, P. (2011). Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. *Psychopharmacology (Berl)*. 215(1):105-15. doi: 10.1007/s00213-010-2122-2.
- Cooke, JD., Grover, LM., Spangler, PR. (2009). Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. *Neuroscience*. 162(4):1411-9. doi: 10.1016/j.neuroscience.2009.05.037.
- Pälvimäki, EP., Laakso, A., Kuoppamäki, M., Syvälahti, E., Hietala, J. (1994). Upregulation of β1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. *Psychopharmacology*. 115: 543. https://doi.org/10.1007/BF02245579
- 21. Yan, Z. (2002). Regulation of GABAergic inhibition by serotonin signalling in prefrontal cortex. *Molecular Neurobiology* 26(2-3) 203-216. doi: 10.1385/MN:26:2-3:203
- Choi, HC., Kim, YI., Song, HK., Kim, JE., Kim, DS., Kang, TC. (2010). Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats. *Brain Res.* 1357:131-41. doi: 10.1016/j.brainres.2010.08.010.

Running Head: fMRI assessment of motor learning and escitalopram

- Mlinar, B., Stocca, G., Corradetti, R. (2015). Endogenous serotonin facilitates hippocampal long-term potentiation at CA3/CA1 synapses. *J Neural Transm(Vienna)*. 122(2):177-85. doi: 10.1007/s00702-014-1246-7.
- 24. Batsikadze, G., Paulus, W., Kuo, MF., Nitsche, MA. (2013). Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex. *Neuropsychopharmacology*, 38(11), 2260-2267. doi:10.1038/npp.2013.127.
- 25. Castrén, E. (2005). Is mood chemistry? *Nat Rev Neurosci*, 6(3), 241-246. doi:10.1038/nrn1629
- 26. Castrén, E. (2013). Neuronal network plasticity and recovery from depression. JAMA *Psychiatry*, 70(9), 983-989. doi:10.1001/jamapsychiatry.2013.1
- Siepmann, T., Penzlin, A.I., Kepplinger, J., Illigens, BM., Weidner, K., Reichmann, H., Barlinn, K. (2015). Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. *Brain Behav*. 23;5(10): e00373. doi: 10.1002/brb3.373.
- Schaefer, A., Burmann, I., Regenthal, R., Arélin, K., Barth, C., Pampel, A., Villringer, A., Margulies, DS., Sacher, J. (2014). Serotonergic modulation of intrinsic functional connectivity. *Current Biology*, 24(19), 2314-2318. doi: 10.1016/j.cub.2014.08.024.
- Knott, VJ., Howson, AL., Perugini, M., Ravindran, AV., & Young, SN. (1999). The Effect of Acute Tryptophan Depletion and Fenfluramine on Quantitative EEG and Mood in Healthy Male Subjects. *Biological Psychiatry*; (46) 229–238.
- 30. Loubinoux, I., Boulanouar, K., Ranjeva, JP., Carel, C., Berry, I., Rascol, O., Celsis, P., Chollet, F. (1999). Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab. 19(12):1365-75. doi: 10.1097/00004647-199912000-00010
- Loubinoux, I., Pariente, J., Boulanouar, K., Carel, C., Manelfe, C., Rascol, O., Celsis, P., Chollet, F. (2002a). A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. *Neuroimage*, 15(1), 26-36. doi:10.1006/nimg.2001.0957.
- Loubinoux, I., Pariente. J., Rascol, O., Celsis, P., Chollet, F. (2002b). Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A doubleblind, placebo-controlled, multi-dose study in healthy subjects. *Neuropsychologia*. 40(11):1815-21.
- Loubinoux, I., Tombari, D., Pariente, J., Gerdelat-Mas, A., Franceries, X., Cassol, E., Rascol, O., Pastor, J., Chollet, F. (2005). Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. *Neuroimage*. 27(2):299-313. doi:10.1016/j.neuroimage.2004.12.023
- 34. Kraglund, KL., Mortensen, JK., Damsbo, AG., Modrau, B., Simonsen, SA., Iversen, HK., Madsen, M., Grove, EL., Johnsen, SP., Andersen, G. (2018). Neuroregeneration and

Running Head: fMRI assessment of motor learning and escitalopram

Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). *Stroke*. 49(11):2568-2576. doi:10.1161/STROKEAHA.117.020067.

- FOCUS Trial Collaboration. (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *Lancet*. 393(10168):265-274. doi: 10.1016/S0140-6736(18)32823-X.
- van der Worp, BH. (2019). Fluoxetine and recovery after stroke. *Lancet.* 393(10168):206-207. doi: 10.1016/S0140-6736(18)32983-0.
- Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., Dudczak, R., Tauscher, J., Kasper S. (2006). In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. *Psychopharmacology (Berl)*. 188(3):263-72. doi:10.1007/s00213-006-0486-0.
- 38. Kasper, S., Spadone C., Verpillat P., Angst J. (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. *Int Clin Psychopharmacol.* 21(2):105-10.

39. Sanchez, C., Reines, EH., Montgomery, SA. (2014). A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? *Int Clin Psychopharmacol.* 29(4):185-96.
doi: 10.1097/YIC.0000000000023.

40. Gryga, M., Taubert, M., Dukart, J., Vollmann, H., Conde, V., Sehm, B., Villringer, A., Ragert, P. (2012). Bidirectional gray matter changes after complex motor skill learning. *Front Syst Neurosci*, 6:37. doi:10.3389/fnsys.2012.00037

- Pasqualetti G., Gori G., Blandizzi C., Del Tacca, M. (2010). Healthy volunteers and early phases of clinical experimentation. *Eur J Clin Pharmacol.*;66(7):647-53. doi: 10.1007/s00228-010-0827-0.
- Karakunnel, JJ., Bui, N., Palaniappan, L., Schmidt, KT., Mahaffey, KW., Morrison, B., Figg., WD., Kummar, S. (2018). Reviewing the role of healthy volunteer studies in drug development. *J Transl Med.* 4;16(1):336. doi: 10.1186/s12967-018-1710-5.
- 43. van Dyck, CH., Malison, RT., Seibyl, JP., Laruelle, M., Klumpp, H., Zoghbi, SS., Baldwin, RM., Innis, RB. (2000) Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiol Aging. 21(4):497-501. doi: 10.1016/s0197-4580(00)00152-4.
- 44. Hampson, E. & Kimura D. (1988). Reciprocal effects of hormonal fluctuations on human motor and perceptual-spatial skills. *Behav Neurosci.* 102(3):456-9. doi:10.1037//0735-7044.102.3.456
- Barth, C., Villringer, A., Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Front Neurosci.* 9:37. doi: 10.3389/fnins.2015.00037.

Running Head: fMRI assessment of motor learning and escitalopram

- LeGates, T., Kvarta, MD., Thompson, SM. (2019). Sex differences in antidepressant efficacy. *Neuropsychopharmacology*;44(1):140-154. doi: 10.1038/s41386-018-0156z.
- 47. Uher, R., Farmer, A., Henigsberg, N., Rietschel, M., Mors, O., Maier, W., Kozel, D., Hauser, J., Souery, D., Placentino, A., Strohmaier, J., Perroud, N., Zobel, A., Rajewska-Rager, A., Dernovsek, MZ., Larsen, E.R., Kalember, P., Giovannini, M., McGuffin, P., Aitchison, KJ. (2009). C., Barreto, Adverse reactions to antidepressants. Br J Psychiatry. 195(3):202-10. doi: 10.1192/bjp.bp.108.061960.
- 48. Rao, N. (2007). The Clinical Pharmacokinetics of Escitalopram. *Clinical Pharmacokinetics* 46(4):281-90. DOI: 10.2165/00003088-200746040-00002.
- 49. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
- Faul, F., Erdfelder, E., Lang, AG, Buchner A. (2007). G\*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. 39(2):175-91. doi:10.3758/bf03193146.
- 51. Iglewicz, B., Banerjee, S. (2001). A simple univariate outlier identification procedure. Proceedings of the Annual Meeting of the American Statistical Association.
- Mugler, JP., 3rd, Brookeman, J.R. (1990). Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). *Magn Reson Med*;15(1):152-157. doi: 10.1002/mrm.1910150117.
- 53. Streitbürger, DP., Pampel, A., Krueger, G., Lepsien, J., Schroeter, ML., Mueller, K., Möller, HE. (2014). Impact of image acquisition on voxel-based-morphometry investigations of age-related structural brain changes. *Neuroimage*. 15; 87:170-82. doi:10.1016/j.neuroimage.2013.10.051.
- 54. Holiga, Š., Mueller, K., Möller, HE., Sieger, T., Schroeter, ML., Vymazal, J. (2013). Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies. *PLoS One*. 2013;8:e56133. doi.org/10.1371/journal.pone.0056133.
- 55. Hardwick, RM., Rottschy, C., Miall, RC., Eickhoff, SB. (2013). A quantitative metaanalysis and review of motor learning in the human brain. *Neuroimage*. 15; 67:283-97. doi: 10.1016/j.neuroimage.2012.11.020.
- Owens, MJ., Knight, DL., Nemeroff, CB. (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. *Biol Psychiatry*. 50(5):345-50. doi: 10.1016/s0006-3223(01)01145-3
- 57. Baird, JF., Gaughan, ME., Saffer, HM., Sarzynski, MA., Herter, TM., Fritz, SL., den Ouden, DB., Stewart, J.C. (2018). The effect of energy-matched exercise intensity on brainderived neurotrophic factor and motor learning. *Neurobiol Learn Mem.* 156:33-44. doi: 10.1016/j.nlm.2018.10.008.
- 58. Grégoire, CA., Berryman, N., St-Onge, F., Vu, TTM., Bosquet, L., Arbour, N., Bherer, L. (2019). Gross Motor Skills Training Leads to Increased Brain-Derived Neurotrophic

Running Head: fMRI assessment of motor learning and escitalopram

Factor Levels in Healthy Older Adults: A Pilot Study. *Front Physiol.* 10: 410. doi:10.3389/fphys.2019.00410.

- Wymbs, FN., & Grafton, ST. (2014). The Human Motor System Supports Sequence-Specific Representations over Multiple Training-Dependent Timescales. *Cerebral Cortex*, 25(11) 4213–4225, doi: https://doi.org/10.1093/cercor/bhu144
- Penhune, VB., Steele, CJ. (2012). Parallel contributions of cerebellar, striatal and M1 mechanisms to motor sequence learning. *Behav Brain Res.* 15;226(2):579-91. doi: 10.1016/j.bbr.2011.09.044.
- 61. Toni, I., Krams, M., Turner, R., Passingham, RE. (1998). The time course of changes during motor sequence learning: a whole-brain fMRI study. *Neuroimage*. 8(1):50-61. doi:https://doi.org/10.1006/nimg.1998.0349
- 62. Luft, AR., Buitrago, MM. (2005). Stages of motor skill learning. *Mol Neurobiol* 32(3):205-16. doi:10.1385/MN:32:3:205.
- 63. Karni, A., Meyer, G., Rey-Hipolito, C., Jezzard, P., Adams, MM., Turner. R., Ungerleider, LG. (1998). The acquisition of skilled motor performance: fast and slow experiencedriven changes in primary motor cortex. *PNAS*;3;95(3):861-8. doi: 10.1073/pnas.95.3.861.
- 64. Hotermans, C., Peigneux, P., Maertens de Noordhout, A., Moonen, G., Maquet, P. (2006). Early boost and slow consolidation in motor skill learning. *Learn Mem.*;13(5):580-3. doi:10.1101/lm.239406
- Poldrack, RA., Sabb, FW., Foerde, K., Tom, SM., Asarnow, RF., Bookheimer, SY., Knowlton, BJ. (2005). The neural correlates of motor skill automaticity. *J Neurosci*. 25(22):5356-64. doi: https://doi.org/10.1523/JNEUROSCI.3880-04.2005
- 66. Yang, J. (2015). The influence of motor expertise on the brain activity of motor task performance: A meta-analysis of functional magnetic resonance imaging studies. *Cogn Affect Behav Neurosci.* 15(2):381-94. doi: 10.3758/s13415-014-0329-0.
- 67. Schneider CL, Majewska AK, Busza A, Williams ZR, Mahon BZ, Sahin B. (2019). Selective serotonin reuptake inhibitors for functional recovery after stroke: Similarities with the critical period and the role of experience-dependent plasticity. *J Neurol*. 1-7. doi: 10.1007/s00415-019-09480-0
- Stagg, CJ., Bachtiar, V., Johansen-Berg, H. (2011). The role of GABA in human motor learning. *Curr Biol.* 21(6):480-4. doi: 10.1016/j.cub.2011.01.069.
- Stagg, CJ., Bachtiar, V., Amadi, U., Gudberg, CA., Ilie, AS., Sampaio-Baptista, C., O'Shea, J., Woolrich, M., Smith, SM., Filippini, N., Near, J., Johansen-Berg H. (2014). Local GABA concentration is related to network-level resting functional connectivity. *Elife*. 25;3:e01465. doi: 10.7554/eLife.01465.
- Chen, Z., Silva, AC., Yang, J., Shen, J. (2005). Elevated endogenous GABA level correlates with decreased fMRI signals in the rat brain during acute inhibition of GABA transaminase. *J Neurosci Res.* 79(3):383-91.

Running Head: fMRI assessment of motor learning and escitalopram


- 71. Bhagwagar, Z., Wylezinska, M., Taylor, M., Jezzard, P., Matthews, PM., Cowen, PJ. (2004). Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. *Am J Psychiatry*. 161(2):368-70. doi: 10.1176/appi.ajp.161.2.368
- 72. El Mansari, M., Sánchez, C., Chouvet, G., Renaud, B., Haddjeri, N. (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. *Neuropsychopharmacology*. 30(7):1269-77. doi:10.1038/sj.npp.1300686
- Lladó-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., Celada, P. (2012). 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. *Cereb Cortex*. 22(7):1487-97. doi: 10.1093/cercor/bhr220.
- 74. Karim, HT., Huppert, TJ., Erickson, KI., Wollam, ME., Sparto, PJ., Sejdić, E., Van Swearingen, JM. (2017). Motor sequence learning-induced neural efficiency in functional brain connectivity. *Behav Brain Res.* 15;319:87-95. doi: 10.1016/j.bbr.2016.11.021.
- 75. Mushiake, H., Inase, M., Tanji, J. (1991). Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements. *J Neurophysiol*;66(3):705-18.
- 76. Halsband, U., Ito, N., Tanji, J., Freund, HJ. (1993). The role of premotor cortex and the supplementary motor area in the temporal control of movement in man. *Brain*;116 (Pt 1):243-66. doi:10.1093/brain/116.1.243.
- 77. Kalaska, JF., Crammond, DJ. (1995). Deciding not to GO: neuronal correlates of response selection in a GO/NOGO task in primate premotor and parietal cortex. *Cereb Cortex.*;5(5):410-28. doi:10.1093/cercor/5.5.410.
- Bianchini, F., Verde, P., Colangeli, S., Boccia, M., Strollo, F., Guariglia, C., Bizzarro, G., Piccardi, L. (2018). Effects of oral contraceptives and natural menstrual cycling on environmental learning. *BMC Womens Health*. 18(1):179. doi: 10.1186/s12905-018-0671- 4.
- Henry, ME., Lauriat, TL., Lowen, SB., Churchill, JH., Hodgkinson, CA., Goldman, D., Renshaw, PF. (2013). Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype. *Psychiatry Res.* 213(3): 217–224. doi:10.1016/j.pscychresns.2013.05.008.
- Finnema, SJ., Nabulsi, NB., Eid, T., Detyniecki, K., Lin, SF., Chen, MK., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, DD., Mercier, J., Hannestad, J. Huang, Y., Carson, RE. Imaging synaptic density in the living human brain. *Sci Transl Med.* 8(348):348ra96. doi: 10.1126/scitranslmed.aaf6667.
- Chen, MK., Mecca, AP., Naganawa, M., Finnema, SJ., Toyonaga, T., Lin, SF., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, JW., Michalak, HR., Nabulsi, NB., Arnsten, AFT., Huang, Y., Carson, RE, van Dyck, CH. (2018). Assessing Synaptic

Running Head: fMRI assessment of motor learning and escitalopram


Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. *JAMA Neurol.* 75(10):1215-1224. doi: 10.1001/jamaneurol.2018.1836.


### Running Head: fMRI assessment of motor learning and escitalopram

# Figures & Figure Legends:




**Figure 1**. **Study design and task:** Following baseline, escitalopram or placebo administration took place for 7 consecutive days. Post baseline, motor training took place at single dose (first day), days 5 and 6, and at steady state (day 7). Motor training on days 5 and 6 was completed outside the scanner. fMRI data were acquired at baseline, single dose, and steady state. Task = Sequential Pinch Force Task, fMRI = Functional Magnetic Resonance Imaging, Force = the yellow bar controlled by the participants, the rise and fall of which was required to match the rise and fall of the blue (reference bar, i.e., the bar controlled by a computer).





**Figure 2. Sequential motor learning: Left:** Significant improvements in lag scores over 5 days of sequential motor training across both escitalopram and placebo. However, despite a significant learning effect, we observed no significant group differences in performance, nor did we observe an interaction effect. **Right:** Comparison of the rate of change between baseline and steady state yield no significant group differences. Bold fonts indicate training completed in the scanner.

### Running Head: fMRI assessment of motor learning and escitalopram



#### Figure 3. Escitalopram-induced decreases in cortical motor responses during sequential

**motor learning:** Orthogonal brain slices showing group dependent changes in the learning contrast over time. Mean functional group response (red) of the escitalopram group (top) and placebo (bottom) at each baseline, single dose, and steady state measurements, as computed by a series of one-sample *t*-tests in SPM12. **Single Dose>Steady State:** Brain regions in the escitalopram group with significant decreases in the learning contrast (blue) between single dose and steady state (top row) show decreases in bilateral premotor and temporal-parietal regions (Table 3). Comparisons between single dose with steady state in the placebo group do not yield any significant changes across time (bottom). **Interaction:** Comparisons of groups over time reveal decreases in the learning contrast signal in the left premotor cortex of the escitalopram group that are not observed in placebo (violet). Consideration of behavioral performance as a variable of interest shows brain regions where changes in the learning contrast positively correlate with improvement in motor performance, also with a peak in the left premotor cortex (overlaid in yellow). All results are shown for sequence-specific learning with *p*<0.05 family-wise error (FWE) correction at a cluster forming threshold of *p*<0.001. All orthogonal planes presented are the same.  $\beta$  = beta value at global maximum coordinate.

#### Running Head: fMRI assessment of motor learning and escitalopram




Figure 4: Correlations between escitalopram plasma levels and cortical premotor response during sequence-specific learning from single dose to steady state: (A) Escitalopram plasma concentrations negatively correlate with changes in the learning contrast in bilateral cortical motor regions, including the premotor cortex (premotor cortex from significant  $2\times 2$  interaction overlaid in yellow), with a peak in the left supramarginal gyrus. (B) Betas containing parameter estimates for error from the left premotor cortex plotted against escitalopram plasma levels at single dose and steady state, respectively. Results refer to the sequence-specific learning contrast and are shown with p<0.05 family-wise error (FWE) correction at a cluster forming threshold of p<0.001. Escit. = escitalopram, ng/ml = nanograms/milliliters.  $\beta$  = beta value at premotor MNI coordinates.

Running Head: fMRI assessment of motor learning and escitalopram

### **Tables:**

**Table 1. Demographic overview:** Group demographic overview and mean single dose and steady state escitalopram plasma concentrations. Group values refer to mean $\pm$ standard deviation. Demographic values rounded to the nearest whole number. Escit. = escitalopram, ASEC = antidepressant side effect checklist-score, kg/m<sup>2</sup> = kilogram force per square meter, u/l = units per liter, ng/ml = nanograms/milliliters.

	Escitalopram (n=31)	Placebo (n=33)	<i>t</i> -value	<i>p</i> -value
Age (years)	$24 \pm 3$	$23 \pm 4$	-0.3	0.74
<b>BMI</b> $(kg/m^2)$	$22 \pm 2$	$21 \pm 2$	-1.3	0.19
Lutropin (u/l)	$2\pm 2$	$1 \pm 2$	-1.2	0.20
Follitropin (u/l)	$3\pm3$	$2 \pm 3$	-1.3	0.19
ASEC single dose	3±3	1±1	3.9	≤0.001
ASEC steady state	1±2	1±1	-0.7	0.48
Escit. single dose (ng/ml)	$20\pm5$	-	-	-
Escit. steady state (ng/ml)	$46 \pm 11$	-	-	-

### Running Head: fMRI assessment of motor learning and escitalopram

Table 2. Comparisons of nested linear mixed effects models and post-hoc testing for sequence-specific lag scores: Model comparisons for computing the omnibus tests for *group* and *time* as well as their interaction effect for both outcome measures.  $\chi^2$  and respective *p*-values were computed from LRT between nested models with results of independent samples *t*-tests and corresponding Bayes Factors on mean single dose, steady state, and absolute rate of improvement scores (deltas). BF<sub>01</sub> = Bayes Factor indicating the likelihood of the alternative hypothesis compared to the null hypothesis. . M±SD = means±standard deviation, LRT = likelihood ratio test, df = degrees of freedom,  $\chi^2$  = Chi-square. \*Significant improvement in model fit.

Mixed Effects Modelling	Fixed Effects	Random effects	LRT	Marginal $R^2$	
			$\chi^2$ (df)	<i>p</i> -value	-
Intercept	-	Subject	-	-	0
Time	time	Subject	3301.3 (24)	≤0.001*	0.2917
Group	group+time	Subject	0.0181 (1)	0.8931	0.2918
Interaction	group*time	Subject	25.722 (24)	0.3674	0.2934
Post-hoc Testing	Escitalopram M±SD	Placebo M±SD	<i>t</i> -value (df)	<i>p</i> -value	Cohen's d/BF <sub>01</sub>
Single dose	99.8±57.9	95.1±67.8	-0.3 (62)	0.76	-0.07/0.26
Steady state	58.1±36.1	63.8±44.1	0.56 (62)	0.57	0.14/0.29
Delta scores	-107.1±56.6	-96.7±59.2	0.71 (62)	0.47	0.18/0.31

### Running Head: fMRI assessment of motor learning and escitalopram

# Table 3. Escitalopram-induced motor network changes in the learning contrast during

**sequence motor learning:** Results of a paired comparison of single dose and steady state within the escitalopram group and subsequent interaction comparisons with placebo. All results obtained with a  $2\times2$  flexible factorial design. T=t-values, Z=z-values, MNI(x,y,z)=MNI peak coordinates, Escit. = escitalopram group.

Brain Region	<i>p</i> (FWE-corr)	Cluster Extent	Т	Z	MNI (x,y,z)
Escit. Paired	p(1  w L-coll)	Clusiel Extelli	1	L	1V11 VI (X, Y, Z)
Left Premotor					
Cortex	< 0.001	913	6.33	5.50	-18, 11,59
		,10	6.25	5.44	-21, 11, 50
			6.17	5.39	-27, 8, 59
<b>Right Premotor</b>					, ,
Cortex	< 0.001	233	6.15	5.38	30, -4, 41
			5.10	4.62	24, -4, 65
			4.28	3.97	30, 2, 62
Left Superior					
Parietal Lobule	< 0.001	260	5.82	5.14	-39, -46, 53
			5.33	4.79	-33, -43, 32
			5.13	4.64	-36, -46, 41
Left Middle	0.025	07	4.07	4.52	40 50 4
Temporal Gyrus	0.025	97	4.97	4.52	-48, -58, -4
I of Comenter			3.33	3.17	-39, -67, 8
Left Superior	<0.001	205	107	1 1 1	10 25 20
Frontal Gyrus	< 0.001	295	4.87	4.44	-18, 35, 38
			4.53	4.17	-18, 44, 20
Dicht Comerien			4.31	4.00	-15, 56, 26
Right Superior Parietal Lobule	< 0.001	257	4.74	4.34	12 61 62
Parietai Lobule	<0.001	237	4.74		12, -61, 62
				3.93	18, -61, 50
Left Postcentral			4.06	3.79	33, -40, 59
Gyrus	< 0.001	215	4.70	4.30	-9, -46, 74
Gyrus	<0.001	213	4.70	4.30	-12, 52, 65
			3.63	3.44	-15, -70, 50
Right Middle			5.05	5.44	-13, -70, 30
Temporal Gyrus	0.002	172	4.67	4.29	42, -58, 11
romporur Gyrus	0.002	112	3.77	3.55	33, -58, 23
			3.68	3.47	27, -76, 11
Interaction			5.00	5.11	
Left Premotor					
Cortex	0.044	82	4.36	4.04	-21, 11, 50
			4.17	3.88	-15, 8, 59
			4.10	3.82	-18, -4, 59
Interaction					, ,
(Sensitivity)					
Left Premotor					
Cortex	0.017	111	4.68	4.29	-21, 11, 50
			4.26	3.95	-15, 8, 59
			4.07	3.80	-27, 5, 56